Table of Content

1 Key Insights

2 Executive Summary of Chondrosarcoma

3 SWOT Analysis for Chondrosarcoma

4 Chondrosarcoma Market Overview at a Glance
4.1 Market Share (%) Distribution of Chondrosarcoma In 2017
4.2 Market Share (%) Distribution of Chondrosarcoma In 2030

5 Disease Background and Overview
5.1 Introduction
5.2 Histological grading
5.3 Classification and characteristics of Chondrosarcoma
5.3.1 Conventional chondrosarcoma
5.3.2 Non-conventional chondrosarcoma
5.4 Signaling pathways involved in chondrosarcoma development
5.5 Biomarkers
5.6 Diagnosis

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 7MM Total Incident Patient Population of Chondrosarcoma
6.3 Assumptions and Rationale
6.4 The United States
6.4.1 Incident Population of Chondrosarcoma in the United States
6.4.2 Type-specific cases of Chondrosarcoma in the United States
6.4.3 Type-specific cases of Primary Chondrosarcoma in the United States
6.4.4 Grade-specific cases of Chondrosarcoma in the United States
6.5 EU5 Countries
6.5.1 Germany
6.5.1.1 Incident Population of Chondrosarcoma in Germany
6.5.1.2 Type-specific cases of Chondrosarcoma in Germany
6.5.1.3 Type-specific cases of Primary Chondrosarcoma in Germany
6.5.1.4 Grade-specific cases of Chondrosarcoma in Germany
6.5.2 France
6.5.2.1 Incident Population of Chondrosarcoma in France
6.5.2.2 Type-specific cases of Chondrosarcoma in France
6.5.2.3 Type-specific cases of Primary Chondrosarcoma in France
6.5.2.4 Grade-specific cases of Chondrosarcoma in France
6.5.3 Italy
6.5.3.1 Incident Population of Chondrosarcoma in Italy
6.5.3.2 Type-specific cases of Chondrosarcoma in Italy
6.5.3.3 Type-specific cases of Primary Chondrosarcoma in Italy
6.5.3.4 Grade-specific cases of Chondrosarcoma in Italy
6.5.4 Spain
6.5.4.1 Incident Population of Chondrosarcoma in Spain
6.5.4.2 Type-specific cases of Chondrosarcoma in Spain
6.5.4.3 Type-specific cases of Primary Chondrosarcoma in Spain
6.5.4.4 Grade-specific cases of Chondrosarcoma in Spain
6.5.5 The United Kingdom
6.5.5.1 Incident Population of Chondrosarcoma in the United Kingdom
6.5.5.2 Type-specific cases of Chondrosarcoma in the United Kingdom
6.5.5.3 Type-specific cases of Primary Chondrosarcoma in the United Kingdom
6.5.5.4 Grade-specific cases of Chondrosarcoma in the United Kingdom
6.6 Japan
6.6.1 Incident Population of Chondrosarcoma in Japan
6.6.2 Type-specific cases of Chondrosarcoma in Japan
6.6.3 Type-specific cases of Primary Chondrosarcoma in Japan
6.6.4 Grade-specific cases of Chondrosarcoma in Japan

7 Treatment and Management
7.1 Treatment Guidelines
7.1.1 NCCN Guidelines
7.1.2 ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

8 Case Study
8.1 Intraspinal Mesenchymal Chondrosarcoma: Report of a Pediatric Case and Literature Review

9 Patient Journey

10 Unmet Needs

11 Emerging Therapies
11.1 AG-120: Agios Pharmaceuticals
11.1.1 Product Description
11.1.2 Clinical Development
11.1.2.1 Clinical trials information
11.1.3 Safety and Efficacy

12 Other Promising Candidates
12.1 Trabectedin: PharmaMar
12.1.1 Product Description
12.1.2 Product development activities
12.1.3 Clinical Development
12.1.3.1 Clinical trials information
12.2 Olutasidenib: Forma Therapeutics
12.2.1 Product Description
12.2.2 Clinical Development
12.2.2.1 Clinical trials information
12.3 INBRX-109: Inhibrx
12.3.1 Product Description
12.3.2 Product Development Activities
12.3.3 Safety and Efficacy
12.4 LY3410738: Eli Lilly and Company
12.4.1 Product Description
12.4.2 Clinical Development
12.4.2.1 Clinical trials information

13 Chondrosarcoma: Seven Major Market Analysis
13.1 Key Findings
13.2 Market Size of Chondrosarcoma in 7MM

14 Market Outlook by Country
14.1 Assumption and Rationale
14.2 United States
14.2.1 Total Market size of Chondrosarcoma
14.2.2 US Drug-level Revenue ($M) for Grade-3 CS Cases
14.2.3 US Drug-level Revenue ($M) for Mesenchymal CS cases
14.2.4 US Drug-level Revenue ($M) for Dedifferentiated CS Cases
14.3 EU5 Countries
14.3.1 Germany
14.3.1.1 Total Market size of Chondrosarcoma
14.3.1.2 Germany Drug-level Revenue ($M) for Grade-3 CS Cases
14.3.1.3 Germany Drug-level Revenue ($M) for Mesenchymal CS cases
14.3.1.4 Germany Drug-level Revenue ($M) for Dedifferentiated CS Cases
14.3.2 France
14.3.2.1 Total Market size of Chondrosarcoma
14.3.2.2 France Drug-level Revenue ($M) for Grade-3 CS Cases
14.3.2.3 France Drug-level Revenue ($M) for Mesenchymal CS cases
14.3.2.4 France Drug-level Revenue ($M) for Dedifferentiated CS Cases
14.3.3 Italy
14.3.3.1 Total Market size of Chondrosarcoma
14.3.3.2 Italy Drug-level Revenue ($M) for Grade-3 CS Cases
14.3.3.3 Italy Drug-level Revenue ($M) for Mesenchymal CS cases
14.3.3.4 Italy Drug-level Revenue ($M) for Dedifferentiated CS Cases
14.3.4 Spain
14.3.4.1 Total Market size of Chondrosarcoma in Spain
14.3.4.2 Market Size by Therapies for Grade-3 Metastatic Chondrosarcoma
14.3.4.3 Market Size by Therapies for Mesenchymal Chondrosarcoma
14.3.4.4 Market Size by Therapies for Dedifferentiated Chondrosarcoma
14.3.5 UK
14.3.5.1 Total Market size of Chondrosarcoma in the UK
14.3.5.2 Market Size by Therapies for Grade-3 Metastatic Chondrosarcoma
14.3.5.3 Market Size by Therapies for Mesenchymal Chondrosarcoma
14.3.5.4 Market Size by Therapies for Dedifferentiated Chondrosarcoma

15 Japan
15.1 Total Market size of Chondrosarcoma in Japan
15.2 Market Size by Therapies for Grade-3 Metastatic Chondrosarcoma
15.3 Market Size by Therapies for Mesenchymal Chondrosarcoma
15.4 Market Size by Therapies for Dedifferentiated Chondrosarcoma

16 Market Drivers

17 Market Barriers

18 Appendix
18.1 Report Methodology

19 DelveInsight Capabilities

20 Disclaimer

21 About DelveInsight



List of Figures


Figure 1: SWOT Analysis
Figure 2: The involved molecular pathways responsible for CH development
Figure 3: Chondrosarcoma signaling
Figure 4: The IHH/PTHrP signaling pathway
Figure 5: Incident Cases of Chondrosarcoma in the 7MM (2017–2030)
Figure 6: Incident Population of Chondrosarcoma in the United States (2017–2030)
Figure 7: Type-specific cases of Chondrosarcoma in the United States (2017–2030)
Figure 8: Type-specific cases of Primary Chondrosarcoma in the United States (2017–2030)
Figure 9: Grade-specific cases of Chondrosarcoma in the United States (2017–2030)
Figure 10: Incident Population of Chondrosarcoma in Germany (2017–2030)
Figure 11: Type-specific cases of Chondrosarcoma in Germany (2017–2030)
Figure 12: Type-specific cases of Primary Chondrosarcoma in Germany (2017–2030)
Figure 13: Grade-specific cases of Chondrosarcoma in Germany (2017–2030)
Figure 14: Incident Population of Chondrosarcoma in France (2017–2030)
Figure 15: Type-specific cases of Chondrosarcoma in France (2017–2030)
Figure 16: Type-specific cases of Primary Chondrosarcoma in France (2017–2030)
Figure 17: Grade-specific cases of Chondrosarcoma in France (2017–2030)
Figure 18: Incident Population of Chondrosarcoma in Italy (2017–2030)
Figure 19: Type-specific cases of Chondrosarcoma in Italy (2017–2030)
Figure 20: Type-specific cases of Primary Chondrosarcoma in Italy (2017–2030)
Figure 21: Grade-specific cases of Chondrosarcoma in Italy (2017–2030)
Figure 22: Incident Population of Chondrosarcoma in Spain (2017–2030)
Figure 23: Type-specific cases of Chondrosarcoma in Spain (2017–2030)
Figure 24: Type-specific cases of Primary Chondrosarcoma in Spain (2017–2030)
Figure 25: Grade-specific cases of Chondrosarcoma in Spain (2017–2030)
Figure 26: Incident Population of Chondrosarcoma in the United Kingdom (2017–2030)
Figure 27: Type-specific cases of Chondrosarcoma in the United Kingdom (2017–2030)
Figure 28: Type-specific cases of Primary Chondrosarcoma in the United Kingdom (2017–2030)
Figure 29: Grade-specific cases of Chondrosarcoma in the United Kingdom (2017–2030)
Figure 30: Incident Population of Chondrosarcoma in Japan (2017–2030)
Figure 31: Type-specific cases of Chondrosarcoma in Japan (2017–2030)
Figure 32: Type-specific cases of Primary Chondrosarcoma in Japan (2017–2030)
Figure 33: Grade-specific cases of Chondrosarcoma in Japan (2017–2030)
Figure 34: Low grade and intracompartmental (CHON-2)
Figure 35: High grade or clear cell or extracompartmental (CHON-3)
Figure 36: Metastatic chondrosarcoma (CHON-4)
Figure 37: Dedifferentiated Chondrosarcoma
Figure 38: Surveillance (OSTEO-4)
Figure 39: (OSTEO-2)
Figure 40: (OSTEO-3)
Figure 41: Treatment of Mesenchymal Chondrosarcoma
Figure 42: Patient Journey
Figure 43: Unmet Needs for chondrosarcoma
Figure 44: Seven Major Market Size of Chondrosarcoma in USD Million (2017–2030)
Figure 45: Market Size of Chondrosarcoma in the United States, USD Millions (2017–2030)
Figure 46: US Drug-level Revenue ($M) for Grade-3 CS Cases (2017–2030)
Figure 47: US Drug-level Revenue ($M) for Mesenchymal CS cases (2017–2030)
Figure 48: US Drug-level Revenue ($M) for Dedifferentiated CS Cases (2017–2030)
Figure 49: Market Size of CHONDROSARCOMA in Germany, Germany USD Millions (2017–2030)
Figure 50: Germany Drug-level Revenue ($M) for Grade-3 CS Cases (2017–2030)
Figure 51: Germany Drug-level Revenue ($M) for Mesenchymal CS cases (2017–2030)
Figure 52: Germany Drug-level Revenue ($M) for Dedifferentiated CS Cases (2017–2030)
Figure 53: Market Size of CHONDROSARCOMA in France, France USD Millions (2017–2030)
Figure 54: France Drug-level Revenue ($M) for Grade-3 CS Cases (2017–2030)
Figure 55: France Drug-level Revenue ($M) for Mesenchymal CS cases (2017–2030)
Figure 56: France Drug-level Revenue ($M) for Dedifferentiated CS Cases (2017–2030)
Figure 57: Market Size of CHONDROSARCOMA in Italy, Italy USD Millions (2017–2030)
Figure 58: Italy Drug-level Revenue ($M) for Grade-3 CS Cases (2017–2030)
Figure 59: Italy Drug-level Revenue ($M) for Mesenchymal CS cases (2017–2030)
Figure 60: Italy Drug-level Revenue ($M) for Dedifferentiated CS Cases (2017–2030)
Figure 61: Market Size of Chondrosarcoma in Spain, USD Millions (2017–2030)
Figure 62: Spain market size by therapies of Grade-3 Metastatic Chondrosarcoma in USD Million (2017–2030)
Figure 63: Spain market size by therapies of Mesenchymal Chondrosarcoma in USD Million (2017–2030)
Figure 64: Spain market size by therapies of Dedifferentiated Chondrosarcoma in USD Million (2017–2030)
Figure 65: Market Size of Chondrosarcoma in the UK, USD Millions (2017–2030)
Figure 66: UK market size by therapies of Grade-3 Metastatic Chondrosarcoma in USD Million (2017–2030)
Figure 67: UK market size by therapies of Mesenchymal Chondrosarcoma in USD Million (2017–2030)
Figure 68: UK market size by therapies of Dedifferentiated Chondrosarcoma in USD Million (2017–2030)
Figure 69: Market Size of Chondrosarcoma in Japan, USD Millions (2017–2030)
Figure 70: Japan market size by therapies of Grade-3 Metastatic Chondrosarcoma in USD Million (2017–2030)
Figure 71: Japan market size by therapies of Mesenchymal Chondrosarcoma in USD Million (2017–2030)
Figure 72: Japan market size by therapies of Dedifferentiated Chondrosarcoma in USD Million (2017–2030)
Figure 73: Market drivers for Chondrosarcoma
Figure 74:Market Barriers for Chondrosarcoma


List of Tables


Table 1: Summary of Chondrosarcoma Market, Epidemiology, and Key Events (2017–2030)
Table 2:Total Incident Patient Population of Chondrosarcoma in the 7MM (2017–2030)
Table 3: Incident Population of Chondrosarcoma in the United States (2017–2030)
Table 4: Type-specific cases of Chondrosarcoma in the United States (2017–2030)
Table 5: Type-specific cases of Primary Chondrosarcoma in the United States (2017–2030)
Table 6: Grade-specific cases of Chondrosarcoma in the United States (2017–2030)
Table 7: Incident Population of Chondrosarcoma in Germany (2017–2030)
Table 8: Type-specific cases of Chondrosarcoma in Germany (2017–2030)
Table 9: Type-specific cases of Primary Chondrosarcoma in Germany (2017–2030)
Table 10: Grade-specific cases of Chondrosarcoma in Germany (2017–2030)
Table 11: Incident Population of Chondrosarcoma in France (2017–2030)
Table 12: Type-specific cases of Chondrosarcoma in France (2017–2030)
Table 13: Type-specific cases of Primary Chondrosarcoma in France (2017–2030)
Table 14: Grade-specific cases of Chondrosarcoma in France (2017–2030)
Table 15: Incident Population of Chondrosarcoma in Italy (2017–2030)
Table 16: Type-specific cases of Chondrosarcoma in Italy (2017–2030)
Table 17: Type-specific cases of Primary Chondrosarcoma in Italy (2017–2030)
Table 18: Grade-specific cases of Chondrosarcoma in Italy (2017–2030)
Table 19: Incident Population of Chondrosarcoma in Spain (2017–2030)
Table 20: Type-specific cases of Chondrosarcoma in Spain (2017–2030)
Table 21: Type-specific cases of Primary Chondrosarcoma in Spain (2017–2030)
Table 22: Grade-specific cases of Chondrosarcoma in Spain (2017–2030)
Table 23: Incident Population of Chondrosarcoma in the United Kingdom (2017–2030)
Table 24: Type-specific cases of Chondrosarcoma in the United Kingdom (2017–2030)
Table 25: Type-specific cases of Primary Chondrosarcoma in the United Kingdom (2017–2030)
Table 26: Grade-specific cases of Chondrosarcoma in the United Kingdom (2017–2030)
Table 27: Incident Population of Chondrosarcoma in Japan (2017–2030)
Table 28: Type-specific cases of Chondrosarcoma in Japan (2017–2030)
Table 29: Type-specific cases of Primary Chondrosarcoma in Japan (2017–2030)
Table 30: Grade-specific cases of Chondrosarcoma in Japan (2017–2030)
Table 31: AG-120, Clinical Trial Description, 2020
Table 32: Trabectedin, Clinical Trial Description, 2020
Table 33: Olutasidenib, Clinical Trial Description, 2020
Table 34: LY3410738, Clinical Trial Description, 2020
Table 35: Seven Major Market Size of Chondrosarcoma in USD Million (2017–2030)
Table 36: The US Market size of Chondrosarcoma in USD Million (2017–2030)
Table 37: US Drug-level Revenue ($M) for Grade-3 CS Cases (2017–2030)
Table 38: US Drug-level Revenue ($M) for Mesenchymal CS cases (2017–2030)
Table 39: US Drug-level Revenue ($M) for Dedifferentiated CS Cases (2017–2030)
Table 40: Germany Market size of Chondrosarcoma in Germany USD Million (2017–2030)
Table 41: Germany Drug-level Revenue ($M) for Grade-3 CS Cases (2017–2030)
Table 42: Germany Drug-level Revenue ($M) for Mesenchymal CS cases (2017–2030)
Table 43: Germany Drug-level Revenue ($M) for Dedifferentiated CS Cases (2017–2030)
Table 44: France Market size of Chondrosarcoma in France USD Million (2017–2030)
Table 45: France Drug-level Revenue ($M) for Grade-3 CS Cases (2017–2030)
Table 46: France Drug-level Revenue ($M) for Mesenchymal CS cases (2017–2030)
Table 47: France Drug-level Revenue ($M) for Dedifferentiated CS Cases (2017–2030)
Table 48: Italy Market size of Chondrosarcoma in Italy USD Million (2017–2030)
Table 49: Italy Drug-level Revenue ($M) for Grade-3 CS Cases (2017–2030)
Table 50: Italy Drug-level Revenue ($M) for Mesenchymal CS cases (2017–2030)
Table 51: Italy Drug-level Revenue ($M) for Dedifferentiated CS Cases (2017–2030)
Table 52: Spain Market size of Chondrosarcoma in USD Million (2017–2030)
Table 53: Spain market size by therapies of Grade-3 Metastatic Chondrosarcoma in USD Million (2017–2030)
Table 54: Spain market size by therapies of Mesenchymal Chondrosarcoma in USD Million (2017–2030)
Table 55: Spain market size by therapies of Dedifferentiated Chondrosarcoma in USD Million (2017–2030)
Table 56: UK Market size of Chondrosarcoma in USD Million (2017–2030)
Table 57: UK market size by therapies of Grade-3 Metastatic Chondrosarcoma in USD Million (2017–2030)
Table 58: UK market size by therapies of Mesenchymal Chondrosarcoma in USD Million (2017–2030)
Table 59: UK market size by therapies of Dedifferentiated Chondrosarcoma in USD Million (2017–2030)
Table 60: Japan Market size of Chondrosarcoma in USD Million (2017–2030)
Table 61: Japan market size by therapies of Grade-3 Metastatic Chondrosarcoma in USD Million (2017–2030)
Table 62: Japan market size by therapies of Mesenchymal Chondrosarcoma in USD Million (2017–2030)
Table 63: Japan market size by therapies of Dedifferentiated Chondrosarcoma in USD Million (2017–2030)